ECSP088873A - Combinación farmaceutica que comprende 3-(3-dimetilamino-1-etil-2-metil-propil) fenol y nsaid - Google Patents
Combinación farmaceutica que comprende 3-(3-dimetilamino-1-etil-2-metil-propil) fenol y nsaidInfo
- Publication number
- ECSP088873A ECSP088873A EC2008008873A ECSP088873A ECSP088873A EC SP088873 A ECSP088873 A EC SP088873A EC 2008008873 A EC2008008873 A EC 2008008873A EC SP088873 A ECSP088873 A EC SP088873A EC SP088873 A ECSP088873 A EC SP088873A
- Authority
- EC
- Ecuador
- Prior art keywords
- components
- phenol
- methyl
- propil
- etil
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
- C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
- C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/84—Unsaturated compounds containing keto groups containing six membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
- C07C69/12—Acetic acid esters
- C07C69/14—Acetic acid esters of monohydroxylic compounds
- C07C69/145—Acetic acid esters of monohydroxylic compounds of unsaturated alcohols
- C07C69/157—Acetic acid esters of monohydroxylic compounds of unsaturated alcohols containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
- C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
- C07D231/48—Oxygen atom in position 3 or 5 and nitrogen atom in position 4 with hydrocarbon radicals attached to said nitrogen atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se relaciona con una combinación que abarca como componentes (a) el compuesto 3-(3-Dimetilamino-1etil-2-metil-propil)-fenol y (b) una o más drogas antiinflamatorias no esferoidales (NSAIDs); una sal farmacéutica que abarca dichos componentes; un compuesto derivado de dichos componentes; una formulación farmacéutica y una forma de dosis que abarca dicha combinación, sal o componente así como un método para tratar el dolor, e.g., dolor agudo o crónico, en un mamífero caracterizado en que los componentes (a) y (b) son administrados simultáneamente o secuencialmente a un mamífero, donde el componente (a) o (b) son administrados a un mamífero por vía oral o por un medio deferente de administración.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06008850 | 2006-04-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP088873A true ECSP088873A (es) | 2008-12-30 |
Family
ID=37025077
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2008008873A ECSP088873A (es) | 2006-04-28 | 2008-11-07 | Combinación farmaceutica que comprende 3-(3-dimetilamino-1-etil-2-metil-propil) fenol y nsaid |
| ECIEPI201713617A ECSP17013617A (es) | 2006-04-28 | 2017-03-06 | combinación farmacéutica que comprende 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y nsaid |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECIEPI201713617A ECSP17013617A (es) | 2006-04-28 | 2017-03-06 | combinación farmacéutica que comprende 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y nsaid |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US20090099138A1 (es) |
| EP (1) | EP2012763B1 (es) |
| JP (1) | JP5543200B2 (es) |
| KR (1) | KR101517064B1 (es) |
| CN (4) | CN101426485B (es) |
| AT (1) | ATE502629T1 (es) |
| AU (1) | AU2007247480B8 (es) |
| BR (1) | BRPI0711482B8 (es) |
| CA (1) | CA2649459C (es) |
| CY (1) | CY1111551T1 (es) |
| DE (1) | DE602007013380D1 (es) |
| DK (1) | DK2012763T3 (es) |
| EC (2) | ECSP088873A (es) |
| ES (1) | ES2358763T3 (es) |
| HR (1) | HRP20110271T1 (es) |
| IL (1) | IL194885A (es) |
| MX (1) | MX2008013828A (es) |
| NO (1) | NO341152B1 (es) |
| NZ (1) | NZ571939A (es) |
| PL (1) | PL2012763T3 (es) |
| PT (1) | PT2012763E (es) |
| RU (1) | RU2465263C2 (es) |
| SI (1) | SI2012763T1 (es) |
| WO (1) | WO2007128412A1 (es) |
| ZA (1) | ZA200810125B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102065852B (zh) * | 2007-11-23 | 2015-06-17 | 格吕伦塔尔有限公司 | 他喷他多组合物 |
| DE102008022520A1 (de) * | 2008-05-07 | 2009-11-12 | Bayer Animal Health Gmbh | Feste Arzneimittelformulierung mit verzögerter Freisetzung |
| HUE043278T2 (hu) * | 2008-09-05 | 2019-08-28 | Gruenenthal Gmbh | 3-(3-dimetilamino-1-etil-2-metil-propil)-fenolt és pregabalint vagy gabapentint tartalmazó gyógyszerkombináció |
| US20100190752A1 (en) | 2008-09-05 | 2010-07-29 | Gruenenthal Gmbh | Pharmaceutical Combination |
| BRPI1014275B8 (pt) | 2009-04-24 | 2021-05-25 | Iceutica Pty Ltd | composição que compreende partículas de indometacina dispersas em pelo menos dois materiais de moagem parcialmente moídos |
| WO2011124953A2 (en) | 2010-04-07 | 2011-10-13 | Lupin Limited | Controlled release pharmaceutical compositions of tapentadol |
| JP6133772B2 (ja) | 2010-06-15 | 2017-05-24 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 痛み治療用の医薬配合物 |
| LT3656765T (lt) | 2010-07-23 | 2021-06-10 | Grünenthal GmbH | 3-(3-dimetilamino-1-etil-2-metil-propil)-fenolio druskos arba bendri kristalai |
| WO2012038974A1 (en) | 2010-09-20 | 2012-03-29 | Ind-Swift Laboratories Limited | Process for preparing l-phenyl-3-dimethylaminopropane derivative |
| MX374468B (es) | 2011-03-04 | 2025-03-06 | Gruenenthal Gmbh | Composicion farmaceutica acuosa semisolida que contiene tapentadol. |
| EA024193B1 (ru) | 2011-03-04 | 2016-08-31 | Грюненталь Гмбх | Фармацевтическая композиция на водной основе, предназначенная для парентерального введения тапентадола |
| MX369121B (es) | 2011-03-04 | 2019-10-30 | Gruenenthal Gmbh | Formulacion farmaceutica acuosa de tapentadol para administracion oral. |
| EP2694049B1 (en) * | 2011-04-05 | 2018-10-31 | Grünenthal GmbH | Tapentadol for preventing chronification of pain |
| NO2701693T3 (es) | 2011-04-29 | 2018-01-20 | ||
| BR112014000969A2 (pt) * | 2011-07-29 | 2017-04-18 | Gruenenthal Gmbh | administração intratecal ou epidural de 3-[(1s,2s)-3-(dimetilamino)- 1-etil-2-metilpropil]fenol |
| US9855286B2 (en) | 2012-05-18 | 2018-01-02 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component |
| US9320729B2 (en) | 2012-05-18 | 2016-04-26 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative |
| US20130310435A1 (en) | 2012-05-18 | 2013-11-21 | Gruenenthal Gmbh | Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol |
| US8912226B2 (en) * | 2012-05-18 | 2014-12-16 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r) -6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a NSAR |
| US9308196B2 (en) * | 2012-05-18 | 2016-04-12 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam |
| US20130310385A1 (en) | 2012-05-18 | 2013-11-21 | Gruenenthal Gmbh | Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants |
| EP2808319A1 (en) | 2013-05-31 | 2014-12-03 | Arevipharma GmbH | 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex |
| EA036258B1 (ru) | 2015-03-27 | 2020-10-20 | Грюненталь Гмбх | Стабильный препарат для парентерального введения тапентадола |
| RU2611659C1 (ru) * | 2015-11-18 | 2017-02-28 | Российская Федерация, от имени которой выступает Федеральное государственное казенное учреждение "Войсковая часть 68240" | Фармацевтическая композиция в виде назального спрея на основе кеторолака и способ ее получения |
| CN109996533A (zh) | 2016-09-23 | 2019-07-09 | 格吕伦塔尔有限公司 | 用于肠胃外施用他喷他多的稳定制剂 |
| EP3585370A1 (en) | 2017-02-23 | 2020-01-01 | Grünenthal GmbH | Tapentadol as local anesthetic |
| CN116253652A (zh) * | 2021-12-09 | 2023-06-13 | 武汉思瓴生物科技有限公司 | 他喷他多的长链脂肪酸酯类衍生物、药学上可接受的盐、药物组合物及制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5133974A (en) * | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| AU661723B2 (en) * | 1991-10-30 | 1995-08-03 | Mcneilab, Inc. | Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug |
| CA2149317A1 (en) * | 1992-12-21 | 1994-07-07 | Richard Wilfred D'souza | Compositions and method for providing improved analgesic effect |
| DE4426245A1 (de) * | 1994-07-23 | 1996-02-22 | Gruenenthal Gmbh | 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung |
| DE10109763A1 (de) * | 2001-02-28 | 2002-09-05 | Gruenenthal Gmbh | Pharmazeutische Salze |
| NZ532278A (en) * | 2001-09-19 | 2006-02-24 | Altana Pharma Ag | Combination of a PDE inhibitor and an NSAID |
| PE20030527A1 (es) * | 2001-10-24 | 2003-07-26 | Gruenenthal Chemie | Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen |
| ATE391498T1 (de) * | 2002-11-22 | 2008-04-15 | Gruenenthal Gmbh | Verwendung von (1rs,3rs,6rs)-6- dimethylaminomethyl-1-(3-methoxy-phenyl)- cyclohexan-1,3-diol zur behandlung von entzündungsschmerz |
| DE102004032103A1 (de) * | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
-
2007
- 2007-04-25 PL PL07724561T patent/PL2012763T3/pl unknown
- 2007-04-25 PT PT07724561T patent/PT2012763E/pt unknown
- 2007-04-25 EP EP07724561A patent/EP2012763B1/en active Active
- 2007-04-25 CN CN2007800146406A patent/CN101426485B/zh not_active Expired - Fee Related
- 2007-04-25 KR KR1020087028979A patent/KR101517064B1/ko not_active Expired - Fee Related
- 2007-04-25 CA CA2649459A patent/CA2649459C/en active Active
- 2007-04-25 MX MX2008013828A patent/MX2008013828A/es active IP Right Grant
- 2007-04-25 AT AT07724561T patent/ATE502629T1/de active
- 2007-04-25 SI SI200730583T patent/SI2012763T1/sl unknown
- 2007-04-25 WO PCT/EP2007/003631 patent/WO2007128412A1/en not_active Ceased
- 2007-04-25 CN CN201510983365.5A patent/CN105561311B/zh not_active Expired - Fee Related
- 2007-04-25 DK DK07724561.1T patent/DK2012763T3/da active
- 2007-04-25 NZ NZ571939A patent/NZ571939A/en not_active IP Right Cessation
- 2007-04-25 JP JP2009506977A patent/JP5543200B2/ja not_active Expired - Fee Related
- 2007-04-25 CN CN201210034660.2A patent/CN102671195B/zh not_active Expired - Fee Related
- 2007-04-25 BR BRPI0711482A patent/BRPI0711482B8/pt active IP Right Grant
- 2007-04-25 HR HR20110271T patent/HRP20110271T1/hr unknown
- 2007-04-25 AU AU2007247480A patent/AU2007247480B8/en not_active Ceased
- 2007-04-25 ES ES07724561T patent/ES2358763T3/es active Active
- 2007-04-25 RU RU2008146815/04A patent/RU2465263C2/ru active
- 2007-04-25 CN CN201210034656.6A patent/CN102675136B/zh not_active Expired - Fee Related
- 2007-04-25 DE DE602007013380T patent/DE602007013380D1/de active Active
- 2007-04-27 US US11/741,411 patent/US20090099138A1/en not_active Abandoned
-
2008
- 2008-10-14 NO NO20084296A patent/NO341152B1/no unknown
- 2008-10-23 IL IL194885A patent/IL194885A/en active IP Right Grant
- 2008-11-07 EC EC2008008873A patent/ECSP088873A/es unknown
- 2008-11-27 ZA ZA200810125A patent/ZA200810125B/xx unknown
-
2011
- 2011-06-14 CY CY20111100559T patent/CY1111551T1/el unknown
-
2013
- 2013-01-30 US US13/754,528 patent/US20130190333A1/en not_active Abandoned
-
2015
- 2015-10-30 US US14/928,016 patent/US20160045459A1/en not_active Abandoned
-
2016
- 2016-08-24 US US15/245,855 patent/US20160361276A1/en not_active Abandoned
-
2017
- 2017-03-06 EC ECIEPI201713617A patent/ECSP17013617A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP088873A (es) | Combinación farmaceutica que comprende 3-(3-dimetilamino-1-etil-2-metil-propil) fenol y nsaid | |
| CY1121492T1 (el) | Φαρμακευτικος συνδυασμος 3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολης και πρεγκαμπαλινης ή γκαμπαπεντινης | |
| ECSP17000643A (es) | Combinación farmacéutica que comprende 3-(3-dimetilamino-1etil-2-metil-propil)-fenol y Paracetamol. | |
| ECSP19047259A (es) | Combinación farmacéutica para el tratamiento del dolor | |
| AR059575A1 (es) | Metodo para el tratamiento de enfermedades inflamatorias | |
| UY32925A (es) | Composiciones de corticosteroides de administración oral | |
| AR065392A1 (es) | Metodos para el tratamiento por inhalacion de una enfermedad o estado respiratorio | |
| BRPI0814666A2 (pt) | composição farmacêutica para a administração oral, uso de uma formulação. processo para a preparação de uma forma de dosagem sólida, e, forma de dosagem sólida | |
| BR112012003280A2 (pt) | composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto. | |
| CL2007002875A1 (es) | Composicion farmaceutica recubierta por una pelicula que comprende capecitabina y al menos un disgregante, util en el tratamiento del cancer para pacientes que tienen dificultad para tragar las formas de dosificacion solidas orales. | |
| ECSP099734A (es) | Composición farmaceutica que comprende la combinación de un agente antiinflamatorio no esteroideo y un agente anticonvulsivante | |
| CO6341550A2 (es) | Combinacion farmaceutica que contiene el 6 - dimetilaminometil - 1 - (3-metoxi-fenil) - ciclohexano - 1,3 - diol y un nsaid. | |
| CO6351711A2 (es) | Combinacion de dosis fija en la forma de una tableta de dos copas o de una sola capa de alisquireno y amlodipina | |
| EA202092800A1 (ru) | Фармацевтическая композиция немедленного высвобождения для противовоспалительных лекарственных средств с фамотидином и карбонатом | |
| ES2328653A1 (es) | Combinacion de sustancias activas para el tratamiento de la diabetes. |